🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

SI-BONE, Inc. SIBN R2K

Healthcare · Medical Devices · United States
https://si-bone.com

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

READ MORE ›
$14.10
-25.40% 1Y

Market & Price

Market Cap
$625.32M
Current Price
$14.10
High / Low (52W)
$21.40 / $11.61
Beta
0.67

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$4.05
Price to Book
3.48
P/S
3.03
EV/EBITDA
-37.85
Dividend Yield
-

Profitability & Returns

ROCE
-7.63%
ROE
-9.64%
ROA
-5.30%
Profit Margin
-8.10%
Op Margin
-9.69%
EPS (Latest Qtr)
$-0.10
EPS (TTM)
$-0.39

Balance Sheet & Liquidity

Debt/Equity
0.24
Quick Ratio
8.20
Current Ratio
9.99
Debt
$42.95M
Total Assets
$238.56M
Current Assets
$216.12M
Working Capital
$190.84M

Ownership

Promoter Holding
3.28%
Chg in Prom Hold
-
FII / Inst Holding
108.07%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$523.59M
Total Revenue (TTM)
$206.22M
EBITDA
$-13.83M
Free Cash Flow
$-2.65M
Operating Cash Flow
$1.87M
Shares Outstanding
44.35M
Gross Margin
79.59%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
23.60%
Profit 5Y
23.05%
Revenue (YoY)
11.20%
Earnings (YoY)
-

PROS

  • Compounding revenue at 23.6% over 5 years.
  • Profit CAGR of 23.0% over 5 years.

CONS

  • Trading 34.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SIBN SI-BONE, Inc. R2K 14.10 - $625.32M - -7.63% -9.64% 23.60% 23.05%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ----14.99M16.32M16.18M16.82M14.05M20.37M20.44M22.19M22.29M22.44M25.59M26.43M32.71M33.30M34.01M37.87M39.97M40.34M47.29M48.63M48.66M56.35M52.59M
Cost of Revenue ----------------------9.60M9.82M9.81M11.82M10.64M
Gross Profit 10.36M11.66M12.48M12.16M13.46M14.73M14.55M14.89M11.93M17.80M18.24M19.82M19.81M19.46M22.12M22.26M26.78M26.99M26.97M29.86M31.58M31.90M37.70M38.81M38.85M44.53M41.94M
Operating Expenses ----------------------45.17M45.81M44.23M46.99M47.04M
Operating Income -5.04M-2.92M-1.70M-3.04M-8.80M-8.14M-10.58M-11.88M-10.14M-8.68M-11.57M-12.96M-13.20M-16.87M-17.88M-13.57M-11.29M-11.96M-11.17M-12.04M-10.08M-7.63M-7.48M-7.00M-5.38M-2.46M-5.09M
EBITDA -----------------------4.60M-4.12M-2.41M624.00K-2.12M
Interest Expense ----------------------662.00K666.00K670.00K630.00K592.00K
Pretax Income -----------------------6.54M-6.15M-4.57M-1.64M-4.33M
Tax Provision ---------------------------
Net Income -5.68M-4.20M-3.15M-4.79M-9.35M-8.65M-11.31M-12.77M-12.47M-9.47M-12.24M-13.98M-15.87M-17.41M-18.51M-14.16M-11.12M-11.21M-10.02M-10.90M-8.94M-6.58M-6.54M-6.15M-4.57M-1.64M-4.33M
Diluted EPS ---------0.44-0.33-0.37-0.42-0.48-0.52-0.54-0.41-0.32-0.30-0.25-0.27-0.22-0.16-0.15-0.14-0.11-0.04-0.10
R&D Expense 1.47M1.21M1.30M1.37M1.68M1.95M1.87M2.09M2.17M2.78M2.96M3.15M3.29M3.58M3.48M3.09M3.29M3.66M3.92M4.34M4.35M3.99M4.53M4.31M4.24M-4.19M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --67.30M73.39M90.15M106.41M138.89M167.18M200.93M
Cost of Revenue -----15.71M29.47M35.06M41.05M
Gross Profit 42.87M50.55M60.51M64.48M79.72M90.70M109.42M132.12M159.88M
Operating Expenses -----150.31M156.35M167.37M182.21M
Operating Income -17.35M-11.96M-36.00M-38.57M-51.67M-59.61M-46.93M-35.25M-22.33M
EBITDA ------54.98M-34.45M-23.09M-10.51M
Interest Expense -----2.82M3.46M3.44M2.63M
Pretax Income ------61.26M-43.34M-30.91M-18.90M
Tax Provision ---------
Net Income -23.04M-17.45M-38.40M-43.70M-56.57M-61.26M-43.34M-30.91M-18.90M
Diluted EPS ----1.50-1.71-1.79-1.13-0.75-0.44
R&D Expense 5.51M5.38M7.28M9.46M12.44M13.63M15.03M16.56M17.45M

Compounded Sales Growth

5 Years:23.60%
1 Year:11.20%

Compounded Profit Growth

5 Years:23.05%
1 Year:-

Stock Price Performance

1 Year:-25.40%
6 Months:-28.32%
3 Months:-9.15%
1 Month:+18.19%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -35.83M138.52M117.01M223.14M-157.55M230.43M230.44M238.56M
Current Assets ------137.61M211.39M207.78M216.12M
Cash & Equivalents 27.90M22.41M25.12M10.44M53.58M-20.72M33.27M34.95M42.24M
Inventory ------17.28M20.25M27.07M33.90M
Receivables ------20.67M21.95M27.46M29.91M
Total Liabilities -46.66M48.33M54.00M53.78M-59.25M61.05M63.47M61.02M
Current Liabilities -7.54M9.01M18.77M13.47M-21.18M23.46M27.13M25.28M
Long Term Debt -38.70M38.96M34.87M39.45M-35.17M36.06M35.45M35.57M
Total Debt ------39.43M38.99M37.48M36.69M
Total Equity -108.73M-129.38M90.19M63.01M169.36M-98.30M169.38M166.96M177.53M
Shares Outstanding ------34.73M40.69M42.09M43.65M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -17.53M-14.52M-31.63M-30.66M--41.66M-18.71M-12.43M-675.00K
Investing Cash Flow -478.00K-97.83M13.49M-62.92M--2.81M-59.80M12.62M4.16M
Financing Cash Flow 12.86M115.15M3.49M136.40M-2.20M90.93M1.96M3.38M
Capital Expenditure -478.00K-942.00K-2.44M-2.56M--9.51M-7.80M-10.50M-8.41M
Free Cash Flow -18.01M-15.46M-34.07M-33.22M--51.16M-26.51M-22.92M-9.09M
Net Change in Cash ------42.27M12.42M2.16M6.86M
Share Buybacks 073.00K38.00K------

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --89.9%87.9%88.4%85.2%78.8%79.0%79.6%
Operating Margin % ---53.5%-52.6%-57.3%-56.0%-33.8%-21.1%-11.1%
Net Margin % ---57.1%-59.5%-62.8%-57.6%-31.2%-18.5%-9.4%
ROE % 17.8%-19.4%-60.9%-25.8%--62.3%-25.6%-18.5%-10.6%
ROCE % -61.3%-9.2%-36.6%-18.4%--43.7%-22.7%-17.3%-10.5%

Shareholding Pattern

Insiders
3.28%
Institutions
108.07%
Public Float
111.74%

Top Institutional Holders

#Holder% HeldSharesValue
1 First Light Asset Management, LLC 12.07% 5.35M $75.48M
2 Blackrock Inc. 7.73% 3.43M $48.34M
3 American Century Companies Inc 5.66% 2.51M $35.38M
4 Brown Advisory Inc. 4.79% 2.12M $29.92M
5 Cadian Capital Management, LP 4.26% 1.89M $26.61M
6 Vanguard Capital Management LLC 3.98% 1.76M $24.88M
7 Granahan Investment Management LLC 3.92% 1.74M $24.52M
8 Impax Asset Management Group plc 3.21% 1.43M $20.09M
9 Nuveen, LLC 2.90% 1.29M $18.13M
10 Silvercrest Asset Management Group, LLC 2.81% 1.24M $17.55M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SIBN

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks